Patient information leaflets for antidepressants: Are patients getting the information they need?

Journal of Affective Disorders

Volumn 128, Issue 1-2, 2011, Pages 165-170

  Haw, Camilla ^a   Stubbs, Jean ^b  

^a St Andrew's Healthcare   (United Kingdom)

^b ST ANDREW S HOSPITAL   (United Kingdom)

Author keywords

Antidepressants; Patient information; Patient information leaflets

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALCOHOL CONSUMPTION; ARTICLE; CONTENT ANALYSIS; DEPRESSION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MECHANISM; HYPERICUM PERFORATUM; MENTAL PATIENT; PATIENT INFORMATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; READING; TREATMENT CONTRAINDICATION; TREATMENT DURATION; UNITED KINGDOM;

ALCOHOL DRINKING; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG LABELING; GREAT BRITAIN; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; HYPERICUM; PAMPHLETS; PATIENT EDUCATION AS TOPIC;

EID: 78649674596     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2010.06.034     Document Type: Article

References (19)

1. British Medical Association & Royal Pharmaceutical Society British National Formulary No 58 2009 BMJ Publishing group London
2. N. Carrigan, D.K. Raynor, and P. Knapp Adequacy of patient information on adverse effects: an assessment of patient information leaflets in the UK Drug Safety 31 2008 305 312
3. Council Directive 92/27/EEC of 31 March 1992 on the labelling of medicinal products for human use and on package leaflets (OJ No. L 113 of 30.4.1992, p.8).
4. Directive 2001/83/EC of 6 November 2001 on the community code relating to medicinal products for human use. (OJ No. L 311 of 28.11.2004, p67-128).
5. Directive 2004/27/EC of 31 March 2004 amending Directive 2001/83/EC on the community code relating to medicinal products for human use (OJ No. L136 of 30.4.2004, p34-57).
6. th.
7. D. Dickinson, D.K. Raynor, and M. Duman Patient information leaflets for medicines: using consumer testing to determine the most effective design Patient Education and Counselling 43 2001 147 159
8. J.G. Edwards, and I. Anderson Systematic review and guide to selective serotonin reuptake inhibitors Drugs 57 1999 507 533
9. B.F. Grant, and T.C. Harford Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey Drug and Alcohol Dependence 39 1995 197 206
10. P. Hammerness, E. Basch, C. Ulbricht, E.P. Barrette, I. Foppa, S. Basch, S. Bent, H. Boon, and E. Ernst St John's Wort: a systematic review of adverse effects and drug interactions for the consultant psychiatrist Psychosomatics 44 2003 271 282
11. A.F. Jorm, H. Christensen, and K.M. Griffiths Belief in the harmfulness of antidepressants: results from a national survey of the Australian public Journal of Affective Disorders 88 2005 47 53
12. R.P.C. Kessels Patients' memory for medical information Journal of Royal Society of Medicine 96 2003 219 222
13. M. Lejoyeux, and J. Adès Antidepressant discontinuation. A review of the literature Journal of Clinical Psychiatry 58 Suppl 7 1997 11 16
14. A.J. Loonen, P.G. Peer, and G.J. Zwanikken Continuation and maintenance therapy with antidepressant agents. Meta-analysis of research Pharmacy Weekly Science 23 1991 167 175
15. Medicines and Healthcare Products Regulatory Authority Always read the leaflet: getting the best information with every medicine 2005 Available at: http://mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON09410
16. Microsoft Office Word, 2003. Microsoft Corporation, Washington.
17. D.K. Raynor, A. Blenkinsopp, P. Knapp, J. Grime, D.J. Nicolson, K. Pollock, G. Dorer, S. Gilbody, D. Dickinson, A.J. Maule, and P. Spoor A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines Health Technology Assessment Vol. 11 2007 No. 5
18. F.W. Reimherr, J.D. Amsterdam, F.M. Quitkin, J.F. Rosenbaum, M. Fava, J. Zajecka, C.M. Beasley, D. Michelson, P. Roback, and K. Sundell Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment American Journal of Psychiatry 155 1998 1247 1253
19. Shrank, W., Avorn, J., Rolon, C., Shekelle, P., 2007. Effect of content and format of prescription drug labels on readability, understanding, and medication use: a systematic review. Annals of Pharmacotherapy Available at: http://www.theannals.com/cgi/content/aph.1H582v1